Ossia M Eichhoff
Overview
Explore the profile of Ossia M Eichhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zila N, Eichhoff O, Steiner I, Mohr T, Bileck A, Cheng P, et al.
Clin Cancer Res
. 2023 Oct;
30(1):159-175.
PMID: 37861398
Purpose: Despite high clinical need, there are no biomarkers that accurately predict the response of patients with metastatic melanoma to anti-PD-1 therapy. Experimental Design: In this multicenter study, we applied...
2.
Eichhoff O, Stoffel C, Kasler J, Briker L, Turko P, Karsai G, et al.
Cancer Res
. 2023 Mar;
83(7):1128-1146.
PMID: 36946761
Significance: Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.
3.
Saltari A, Dzung A, Quadri M, Tiso N, Facchinello N, Hernandez-Barranco A, et al.
Cancer Res
. 2021 Oct;
81(23):6044-6057.
PMID: 34645608
CD271 (NGFR) is a neurotrophin receptor that belongs to the tumor necrosis receptor (TNFR) family. Upon ligand binding, CD271 can mediate either survival or cell death. Although the role of...
4.
Dilshat R, Fock V, Kenny C, Gerritsen I, Lasseur R, Travnickova J, et al.
Elife
. 2021 Jan;
10.
PMID: 33438577
The microphthalmia-associated transcription factor (MITF) is a critical regulator of melanocyte development and differentiation. It also plays an important role in melanoma where it has been described as a molecular...
5.
Zila N, Bileck A, Muqaku B, Janker L, Eichhoff O, Cheng P, et al.
Clin Proteomics
. 2018 Mar;
15:13.
PMID: 29541007
Background: MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but development of drug resistance within a median progression-free survival (PFS) of 9-12 months....
6.
Viswanathan V, Ryan M, Dhruv H, Gill S, Eichhoff O, Seashore-Ludlow B, et al.
Nature
. 2017 Jul;
547(7664):453-457.
PMID: 28678785
Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and...
7.
Widmer D, Eichhoff O, Dummer R, Levesque M
Exp Dermatol
. 2015 May;
24(9):659-60.
PMID: 25977109
No abstract available.
8.
Cheng P, Shakhova O, Widmer D, Eichhoff O, Zingg D, Frommel S, et al.
Genome Biol
. 2015 Apr;
16:42.
PMID: 25885555
Background: Melanoma is the most fatal skin cancer displaying a high degree of molecular heterogeneity. Phenotype switching is a mechanism that contributes to melanoma heterogeneity by altering transcription profiles for...
9.
Widmer D, Hoek K, Cheng P, Eichhoff O, Biedermann T, Raaijmakers M, et al.
J Invest Dermatol
. 2013 Mar;
133(10):2436-2443.
PMID: 23474946
We have previously reported a model for melanoma progression in which oscillation between melanoma cell phenotypes characterized by invasion or proliferation is fundamental to tumor heterogeneity and disease progression. In...
10.
Bottcher-Haberzeth S, Biedermann T, Pontiggia L, Braziulis E, Schiestl C, Hendriks B, et al.
J Invest Dermatol
. 2012 Sep;
133(2):316-24.
PMID: 22971848
Recently, Biedermann et al. (2010) have demonstrated that human eccrine sweat gland cells can develop a multilayered epidermis. The question still remains whether these cells can fulfill exclusive and very...